Laser debulking and drug-eluting balloons for in-stent restenosis: A light at the end of the tunnel?

Journal of Endovascular Therapy

Volumn 20, Issue 6, 2013, Pages 815-818

  Van Den Berg, Jos C ^a  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IOPROMIDE; PACLITAXEL; BIOMATERIAL;

ARTERY OCCLUSION; ATHERECTOMY DEVICE; COST EFFECTIVENESS ANALYSIS; CRITICAL LIMB ISCHEMIA; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DRUG COATING; DRUG ELUTING STENT; EXCIMER LASER; FOLLOW UP; HEART DISEASE; HUMAN; HYPERPLASIA; IN-STENT RESTENOSIS; INCIDENCE; LIMB SALVAGE; LONG TERM CARE; NITINOL STENT; NOTE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POPLITEAL ARTERY; PRIORITY JOURNAL; RECURRENT DISEASE; REVASCULARIZATION; SELF EXPANDING STENT; SUPERFICIAL FEMORAL ARTERY; VASCULAR PATENCY; ATHERECTOMY; CENTRAL VENOUS CATHETER; EQUIPMENT; FEMALE; FEMORAL ARTERY; ISCHEMIA; LASER; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; STENT;

ANGIOPLASTY, BALLOON; ATHERECTOMY; COATED MATERIALS, BIOCOMPATIBLE; FEMALE; FEMORAL ARTERY; HUMANS; ISCHEMIA; LASERS; MALE; PERIPHERAL ARTERIAL DISEASE; STENTS; VASCULAR ACCESS DEVICES;

EID: 84890054167     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1583/13-4308C.1     Document Type: Note

References (21)

1. Diehm NA, Hoppe H, Do DD. Drug eluting balloons. Tech Vasc Interv Radiol. 2010;13:59-63.
2. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-276.
3. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745-2749.
4. Siablis D, Karnabatidis D, Katsanos K, et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol. 2009;20:1141-1150.
5. Gandini R, Del Giudice C, Merolla S, et al. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drugeluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study. J Endovasc Ther. 2013;20:805-814.
6. Schillinger M, Mlekusch W, Haumer M, et al. Angioplasty and elective stenting of de novo versus recurrent femoropopliteal lesions: 1-year follow-up. J Endovasc Ther. 2003;10:288-297.
7. Dick P, Sabeti S, Mlekusch W, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology. 2008;248:297-302.
8. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16-23.
9. Armstrong EJ, Singh S, Singh GD, et al. Angiographic characteristics of femoropopliteal in-stent restenosis: association with longterm outcomes after endovascular intervention. Catheter Cardiovasc Interv. 2013 Apr 30. [Epub ahead of print]
10. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358-1365.
11. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-699.
12. Scheller B, Hehrlein C, Bocksch W, et al. Two year follow-up after treatment of coronary instent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2008;97:773-781.
13. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus pac-litaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119:2986-2994.
14. Stabile E, Virga V, Salemme L, et al. Drugeluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol. 2012;60:1739-1742.
15. Yeo KK, Malik U, Laird JR. Outcomes following treatment of femoropopliteal in-stent restenosis: a single center experience. Catheter Cardiovasc Interv. 2011;78:604-608.
16. Van Den Berg JC, Pedrotti M, Canevascini R, et al. Endovascular treatment of in-stent restenosis using excimer laser angioplasty and drug eluting balloons. J Cardiovasc Surg (Torino). 2012;53:215-222.
17. Werk M, Albrecht T, Meyer DR, et al. Paclitaxelcoated balloons reduce restenosis after femo-ro- popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831-840.
18. Derksen WJ, Gisbertz SS, Hellings WE, et al. Predictive risk factors for restenosis after remote superficial femoral artery endarterectomy. Eur J Vasc Endovasc Surg. 2010;39:597-603.
19. Ho GH, van Buren PA, Moll FL, et al. The importance of revision of early restenosis after endovascular remote endarterectomy in SFA occlusive disease. Eur J Vasc Endovasc Surg. 2000;19:35-42.
20. Ihnat DM, Duong ST, Taylor ZC, et al. Contemporary outcomes after superficial femoral artery angioplasty and stenting: the influence of TASC classification and runoff score. J Vasc Surg. 2008;47:967-974.
21. Iida O, Uematsu M, Soga Y, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011;78:611-617.